Actavis launches generic equivalent of long-acting ADHD drug, with 180-day exclusivity
FDA recently approved methylphenidate hydrochloride extended-release capsules (LA) CII, USP, the generic equivalent of Ritalin LA. Actavis Group, an international generic pharmaceuticals company, received first-to-file exclusivity on the 20-mg, 30-mg, and 40-mg strengths.
FDA recently approved methylphenidate hydrochloride extended-release capsules (LA) CII, USP, the generic equivalent of Ritalin LA. Actavis Group, an international generic pharmaceuticals company, received first-to-file exclusivity on the 20-mg, 30-mg, and 40-mg strengths.
Distribution of the product has begun in the United States.
Methylphenidate hydrochloride extended-release capsules (20 mg, 30 mg, and 40 mg) had U.S. sales of approximately $80.7 million for the 12 months ending September 30, 2011, according to IMS Health.
Doug Boothe, CEO of Actavis in the United States, said in a press release: “The approval and launch of methylphenidate hydrochloride extended-release capsules (LA) offers a significant value to our customers and patients. This approval, along with the first-to-file exclusivity, also underscores Actavis’ emphasis and commitment to bringing complex controlled-release products to the marketplace.”
Prescribing information is available at the Actavis website.
Psychiatric Pharmacist Working to Optimize Treatment, Improve Patient Safety
December 13th 2024A conversation with Nina Vadiei, PharmD, BCPP, clinical associate professor in the Division of Pharmacotherapy at University of Texas at Austin College of Pharmacy and a clinical pharmacy specialist in psychiatry at the San Antonio State Hospital.
